Related references
Note: Only part of the references are listed.
Article
Biochemistry & Molecular Biology
Zhen Cui et al.
Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly worldwide due to its increased fitness, with spike structures that maintain stability for receptor recognition but compromise viral fusion efficiency. By altering amino acids and structures, it evades recognition by most antibodies, facilitating immune escape. The research sheds light on conserved regions for the development of broad-spectrum vaccines.
Article
Immunology
Lu Lu et al.
Summary: Immune sera from BNT162b2 and Coronavac recipients showed reduced neutralizing antibody titers against the omicron variant. The presence of the spike R346K mutation did not affect the neutralization susceptibility.
CLINICAL INFECTIOUS DISEASES
(2022)
Letter
Medicine, General & Internal
Constanze Kuhlmann et al.
Article
Multidisciplinary Sciences
Jinyan Liu et al.
Summary: This study demonstrates that cellular immunity induced by current SARS-CoV-2 vaccines is highly conserved to the Omicron spike protein. Individuals vaccinated with Ad26.COV2.S or BNT162b2 vaccines showed durable spike-specific CD8(+) and CD4(+) T cell responses that were cross-reactive to both the Delta and Omicron variants, including in central and effector memory cellular subpopulations.
Article
Biochemistry & Molecular Biology
Yu Gao et al.
Summary: This study found that SARS-CoV-2 spike-specific CD4(+) and CD8(+) T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against the Omicron variant. Additionally, T cells induced by BNT162b2 vaccination exhibit higher cross-reactivity to the Omicron variant compared to T cells induced by prior SARS-CoV-2 infection.
Article
Cell Biology
Catherine Riou et al.
Summary: This study evaluated neutralizing antibody and T cell responses in patients infected with the Beta variant and those infected before its emergence. It found that CD4 and CD8 T cell responses to Beta were preserved overall, despite loss of recognition of immunogenic CD4 epitopes.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
News Item
Medicine, General & Internal
Luke Taylor
BMJ-BRITISH MEDICAL JOURNAL
(2022)
Article
Oncology
Runhong Zhou et al.
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Correction
Multidisciplinary Sciences
Roanne Keeton et al.
Review
Virology
Nicholas Magazine et al.
Summary: This review summarizes the potential mechanisms by which common mutations on the spike protein in SARS-CoV-2 variants enhance the overall fitness of the virus. Understanding how these mutations alter viral functions can help predict the effects of future mutations and assist the scientific community in addressing viral evolution.
Article
Medicine, General & Internal
Qiaoli Peng et al.
Summary: This study compares the immunogenicity and durability of BNT162b2-mRNA and CoronaVac-inactivated vaccines in fully vaccinated individuals in Hong Kong. The results show that both vaccines induce neutralizing antibodies and spike-specific CD4 T cell responses, but CoronaVac vaccine induces lower immune responses compared to BNT162b2 vaccine. Against SARS-CoV-2 variants of concern, CoronaVac vaccine shows weaker neutralizing antibody responses compared to BNT162b2 vaccine. Three months after vaccination, neutralizing antibody levels to variants of concern decrease, along with waning memory T cell responses, especially among CoronaVac vaccine recipients.
Article
Medicine, General & Internal
Merryn Voysey et al.
Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.
Article
Cell Biology
Zijun Wang et al.
Summary: The IgA response to SARS-CoV-2 was characterized in a cohort of 149 convalescent individuals after COVID-19 diagnosis. IgA responses in plasma generally correlated with IgG responses, and B cells producing IgM, IgG, and IgA were derived from common progenitor cells. Notably, IgA dimers were found to be 15 times more potent than IgA monomers against SARS-CoV-2, suggesting their potential value for protection and vaccine efficacy.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Emma C. Thomson et al.
Summary: SARS-CoV-2 virus can mutate and evade immunity, with mutations like N439K conferring resistance against neutralizing monoclonal antibodies and enhancing binding affinity to hACE2 receptor. Despite similar in vitro replication fitness and clinical outcomes compared to wild type, N439K mutation highlights the importance of ongoing molecular surveillance for guiding vaccine and therapeutic development and usage.
Article
Biochemistry & Molecular Biology
Patrick Tang et al.
Summary: mRNA COVID-19 vaccines demonstrate high effectiveness in preventing severe outcomes and death caused by the Delta variant in Qatar, despite lower effectiveness at blocking infection.
Article
Multidisciplinary Sciences
Pengfei Wang et al.
Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.
Article
Multidisciplinary Sciences
Steven A. Kemp et al.
Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.
Article
Immunology
Kai Wu et al.
Summary: The study evaluated the efficacy of two updated mRNA vaccines targeting SARS-CoV-2 variants in mice. The vaccine based on B.1.351 was effective at increasing neutralizing antibody titers, while the 1:1 mix vaccine provided broad cross-variant neutralization. A third dose of vaccine significantly increased neutralization titers.
Article
Biochemistry & Molecular Biology
Xianding Deng et al.
Summary: A new SARS-CoV-2 variant named B.1.427/B.1.429 was identified in California, with increased transmissibility and carrying three mutations in spike protein, including L452R substitution. The variant emerged in May 2020 and became predominant in sequenced cases from September 2020 to January 2021. In vivo viral shedding was increased and antibody neutralization decreased, calling for further investigation.
Article
Microbiology
Pengfei Wang et al.
Summary: The emerging Brazilian variant P.1 shows increased resistance to antibody neutralization, posing a threat to current antibody therapies, but has less impact on the effectiveness of protective vaccines.
CELL HOST & MICROBE
(2021)
Letter
Cell Biology
Shuai Xia et al.
Article
Medicine, General & Internal
Juan Corchado-Garcia et al.
Summary: This study evaluated the effectiveness of the Johnson & Johnson Ad26.COV2.S vaccine in preventing SARS-CoV-2 infection, finding that the incidence rate of infection was significantly reduced in vaccinated individuals, with an effectiveness of 73.6%.
Article
Medicine, General & Internal
Ezgi Hacisuleyman et al.
Summary: Despite evidence of vaccine efficacy, two fully vaccinated individuals developed mild symptoms of Covid-19 and were infected with variants of SARS-CoV-2. Sequencing of the virus isolates revealed novel mutations, highlighting the potential risk of illness post-vaccination and subsequent infection with variant virus. Efforts to prevent, diagnose, and characterize variants in vaccinated individuals are crucial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Xing Zhu et al.
Summary: The UK variant of SARS-CoV-2 with the N501Y mutation shows increased infectivity due to tighter binding with the ACE2 receptor, but without significant structural changes. Important neutralization epitopes in the spike receptor binding domain are retained.
Review
Microbiology
Alba Grifoni et al.
Summary: This review summarizes recent studies on SARS-CoV-2 T cell epitopes, highlighting the significant correlation between epitope number and antigen size. It also presents an analysis of 1,400 different reported SARS-CoV-2 epitopes and identifies discrete immunodominant regions of the virus and more prevalently recognized epitopes.
CELL HOST & MICROBE
(2021)
Editorial Material
Immunology
Stanley C. Jordan et al.
CELLULAR & MOLECULAR IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Nawal Al Kaabi et al.
Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Letter
Medicine, General & Internal
Emma C. Wall et al.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.
Article
Biochemistry & Molecular Biology
Angela Choi et al.
Summary: The study demonstrates that both the mRNA-1273 COVID-19 vaccine and its variant-modified booster doses are safe and effective in improving neutralizing antibody titers against various virus variants.
Review
Genetics & Heredity
Kaiming Tao et al.
Summary: The emergence of multiple SARS-CoV-2 variants has significant impacts on the epidemiological and clinical aspects of the COVID-19 pandemic, including increased virus transmission rates, heightened risk of reinfection, and reduced effectiveness of neutralizing antibodies and vaccines. These variants have introduced new challenges to COVID-19 research, necessitating additional avenues of laboratory, epidemiological, and clinical studies.
NATURE REVIEWS GENETICS
(2021)
Letter
Medicine, General & Internal
Jocelyn Keehner et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Sophie M-C Gobeil et al.
Summary: SARS-CoV-2 variants with multiple spike mutations have increased transmission and resistance to antibodies. Research showed that these variants have enhanced receptor binding and a preference for receptor binding domain up states. Different variants exhibit different mechanisms for resistance to neutralizing antibodies, which helps explain their transmission and resistance.
Article
Multidisciplinary Sciences
Yongfei Cai et al.
Summary: The study found that the B.1.1.7 variant has increased receptor binding affinity, while the B.1.351 variant has developed resistance to some neutralizing antibodies by reshaping antigenic surfaces on the spike protein.
Article
Immunology
Chia Siang Kow et al.
Summary: This study summarized the overall vaccine effectiveness of the BNT162b2 mRNA vaccine through meta-analyses, finding significant protective effects against COVID-19 confirmed by RT-PCR ≥14 days after the first dose and ≥7 days after the second dose.
INFLAMMOPHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Petra Mlcochova et al.
Summary: The B.1.617.2 (Delta) variant of SARS-CoV-2 has lower sensitivity to antibodies and higher replication efficiency compared to other lineages, which may contribute to its dominance and reduced vaccine effectiveness, highlighting the need for continued infection control measures post-vaccination.
Article
Cell Biology
Alison Tarke et al.
Summary: The study showed that SARS-CoV-2 variants do not significantly disrupt total T cell reactivity, although decreases in response frequency of 10%-22% were observed under certain assay/VOC combinations. This underscores the importance of actively monitoring T cell responses in the context of SARS-CoV-2 evolution.
CELL REPORTS MEDICINE
(2021)
Article
Medicine, Research & Experimental
Bezawit A. Woldemeskel et al.
Summary: Recent studies have shown that T cells can cross-recognize spike proteins of SARS-CoV-2 and common cold coronaviruses. Vaccination with SARS-CoV-2 mRNA vaccines results in broad T cell responses to the virus's spike protein, including potential recognition of variant spike proteins. Additionally, post-vaccination, there is an observed increase in CD4(+) T cell responses to certain common cold coronaviruses.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Immunology
Xiao-Ning Li et al.
Summary: The two-dose inactivated SARS-CoV-2 vaccine showed an effectiveness of 59.0% to 70.2% against the Delta variant, with higher efficacy among participants aged 40-59 years and in females compared to males in preventing COVID-19 and moderate diseases.
EMERGING MICROBES & INFECTIONS
(2021)
Article
Biochemistry & Molecular Biology
Tyler N. Starr et al.
Article
Immunology
Runhong Zhou et al.
Article
Biochemistry & Molecular Biology
Leonid Yurkovetskiy et al.
Article
Medicine, General & Internal
Kizzmekia S. Corbett et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Multidisciplinary Sciences
Donald J. Benton et al.
Article
Immunology
Li Liu et al.
EMERGING MICROBES & INFECTIONS
(2020)
Article
Medicine, Research & Experimental
Li Liu et al.
